Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2024
Spring on the Road
Spring Wellness 2025
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
Parcel Pick Up
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
ADMA Biologics Inc - Common Stock
(NQ:
ADMA
)
18.43
+0.52 (+2.90%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about ADMA Biologics Inc - Common Stock
< Previous
1
2
3
4
5
6
Next >
What's Driving the Market Sentiment Around ADMA Biologics?
March 11, 2025
Via
Benzinga
Adma Biologics' Retail Traders Eye Higher Open After Blowout Q4, Strong Full-Year Outlook
March 03, 2025
CEO Adam Grossman highlighted a 65% year-over-year jump in total revenue and a staggering 309% increase in adjusted EBITDA for 2024.
Via
Stocktwits
Earnings Scheduled For March 3, 2025
March 03, 2025
Via
Benzinga
Peering Into ADMA Biologics's Recent Short Interest
January 22, 2025
Via
Benzinga
How Is The Market Feeling About ADMA Biologics?
December 30, 2024
Via
Benzinga
Looking Into ADMA Biologics's Recent Short Interest
December 05, 2024
Via
Benzinga
(ADMA) - Analyzing ADMA Biologics's Short Interest
October 22, 2024
Via
Benzinga
Top 5 Biotech Stocks That Got Most Retail Buzz Last Week
February 17, 2025
From merger updates to earnings surprises, these healthcare stocks saw the biggest spike in Stocktwits chatter.
Via
Stocktwits
Jim Cramer Likes This Tech Stock: 'Terrific Business, Niche Business'
January 30, 2025
On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Keysight Technologies calling it a "Terrific business."
Via
Benzinga
There May Still Be Time to Get in on These 3 Trending Biotechs
January 20, 2025
Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025.
Via
MarketBeat
Topics
ETFs
Economy
Exposures
Economy
Interest Rates
SpringWorks Therapeutics Stock Sees RS Rating Jump To 86
January 13, 2025
On Monday, SpringWorks Therapeutics stock hit a key technical milestone, seeing its Relative Strength Rating jump to 86.
Via
Investor's Business Daily
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
January 09, 2025
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Government
Exposures
Artificial Intelligence
Political
Key Takeaways From ADMA Biologics Analyst Ratings
October 14, 2024
Via
Benzinga
SpringWorks Therapeutics Stock Gets A RS Rating Lift
January 08, 2025
The Relative Strength (RS) Rating for SpringWorks Therapeutics stock entered a higher percentile Wednesday, as it got a lift from 62 to 76.
Via
Investor's Business Daily
Arcellx Stock Earns 82 Relative Strength Rating
December 27, 2024
Arcellx stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 79 to 82.
Via
Investor's Business Daily
NewAmsterdam Pharma Stock Hits 90-Plus RS Rating
December 11, 2024
NewAmsterdam Pharma stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 74 to 95.
Via
Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
December 02, 2024
Via
Benzinga
BioNTech Stock Got A IBD RS Rating Lift
November 14, 2024
A Relative Strength Rating upgrade for BioNTech ADR shows improving technical performance.
Via
Investor's Business Daily
While growth is established for NASDAQ:ADMA, the stock's valuation remains reasonable.
November 12, 2024
For those who appreciate growth without the sticker shock, NASDAQ:ADMA is worth considering.
Via
Chartmill
This Is What Whales Are Betting On ADMA Biologics
October 10, 2024
Via
Benzinga
IBD 50's Top Stock, ADMA Biologics, Crashes After Auditor Unexpectedly Resigns
October 10, 2024
The company reiterated its outlook for 2024 and 2025.
Via
Investor's Business Daily
Vericel Stock Sees RS Rating Shoot Higher
November 11, 2024
The Relative Strength (RS) Rating for Vericel stock entered a higher percentile Monday, as it got a lift from 69 to 79.
Via
Investor's Business Daily
Buckle Up And Use Volitility To Your Advantage
November 03, 2024
The Advance/Decline trend on the NYSE weakened; the Nasdaq A/D line is outright scary.
Via
Talk Markets
What You Missed On Wall Street This Past Friday
November 03, 2024
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.
Via
Talk Markets
Amazon Posts Upbeat Results, Joins Cardinal Health, Waters, Atlassian, Charter Communications, MasTec And Other Big Stocks Moving Higher On Friday
November 01, 2024
Via
Benzinga
ADMA Biologics, A Top 1% Stock, Skyrockets After Settling Its Accounting Debacle
November 01, 2024
The company signed on a new accounting firm less than a month after its previous accountant resigned unexpectedly.
Via
Investor's Business Daily
Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgrade
October 15, 2024
Amphastar hit an all-time high in August 2023 and consolidated. It could be forming the right side of a cup base that started in January.
Via
Investor's Business Daily
Alkermes Stock Jumps Nearly 30% In 3 Months Amid Hefty Profits
October 14, 2024
Alkermes develops treatments for neurodegenerative diseases (conditions that damage and destroy parts of the nervous system) and cancer.
Via
Investor's Business Daily
CVS Has 'Real Value,' Jim Cramer Says: Micron Had An 'Amazing' Quarter
October 11, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
October 10, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.